MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Phase 4
Completed
Conditions
Arthroplasty, Replacement
Prevention of Venous Thromboembolism
Moderate Renal Impairment (CrCl 30-50 mL/Min)
Interventions
First Posted Date
2010-08-19
Last Posted Date
2018-09-25
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
142
Registration Number
NCT01184989
Locations
🇫🇮

1160.86.35801 Boehringer Ingelheim Investigational Site, Jyväskylä, Finland

🇨🇦

1160.86.01001 Boehringer Ingelheim Investigational Site, Red Deer, Alberta, Canada

🇨🇦

1160.86.01002 Boehringer Ingelheim Investigational Site, Halifax, Nova Scotia, Canada

and more 7 locations

30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks

First Posted Date
2010-08-17
Last Posted Date
2014-10-20
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
936
Registration Number
NCT01183013
Locations
🇺🇸

1264.3.01006 Boehringer Ingelheim Investigational Site, Norwalk, California, United States

🇺🇸

1264.3.01044 Boehringer Ingelheim Investigational Site, Charlotte, North Carolina, United States

🇺🇸

1264.3.01084 Boehringer Ingelheim Investigational Site, Cartersville, Georgia, United States

and more 129 locations

Telmisartan, Amlodipine and Combination in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: amlodipine/telmisartan/combination
First Posted Date
2010-08-13
Last Posted Date
2014-07-24
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
28
Registration Number
NCT01181011
Locations
🇨🇳

1235.30.86001 Boehringer Ingelheim Investigational Site, Shanghai, China

Tiotropium Bromide in Cystic Fibrosis

Phase 3
Completed
Conditions
Cystic Fibrosis
Interventions
Drug: Placebo Respimat® inhaler
First Posted Date
2010-08-11
Last Posted Date
2013-12-24
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
464
Registration Number
NCT01179347
Locations
🇺🇸

205.438.01019 Boehringer Ingelheim Investigational Site, Cleveland, Ohio, United States

🇦🇺

205.438.61001 Boehringer Ingelheim Investigational Site, Adelaide, South Australia, Australia

🇨🇦

205.438.02001 Boehringer Ingelheim Investigational Site, Sherbrooke, Quebec, Canada

and more 96 locations

Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

Phase 3
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: BI 10773 open label
Drug: Placebo identical to BI10773 low dose
Drug: Placebo identical to Sitagliptin 100mg
Drug: Placebo identical to BI10773 high dose
First Posted Date
2010-08-09
Last Posted Date
2014-06-16
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
986
Registration Number
NCT01177813
Locations
🇧🇪

1245.20.32016 Boehringer Ingelheim Investigational Site, Deurne, Belgium

🇺🇸

1245.20.10154 Boehringer Ingelheim Investigational Site, Chino, California, United States

🇺🇸

1245.20.10078 Boehringer Ingelheim Investigational Site, Tampa, Florida, United States

and more 121 locations

Survey on Long-Term Use of BI-Sifrol® Tablets in Patients With Restless Legs Syndrome

Completed
Conditions
Restless Legs Syndrome
First Posted Date
2010-08-03
Last Posted Date
2014-08-29
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
571
Registration Number
NCT01174459
Locations
🇯🇵

Boehringer Ingelheim Investigational Site 94, Toyokawa, Japan

🇯🇵

Boehringer Ingelheim Investigational Site 151, Kumamoto, Japan

🇯🇵

Boehringer Ingelheim Investigational Site 82, Gifu, Japan

and more 156 locations

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: Placebo
Drug: 50 mcg salmeterol HFA MDI
First Posted Date
2010-07-30
Last Posted Date
2014-06-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1071
Registration Number
NCT01172808
Locations
🇧🇷

205.418.55002 Boehringer Ingelheim Investigational Site, Juiz de Fora, Brazil

🇺🇸

205.418.01004 Boehringer Ingelheim Investigational Site, Coeur d'Alene, Idaho, United States

🇺🇸

205.418.01013 Boehringer Ingelheim Investigational Site, North Dartmouth, Massachusetts, United States

and more 111 locations

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: placebo
Drug: 50 mcg salmeterol HFA MDI
First Posted Date
2010-07-30
Last Posted Date
2014-06-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1032
Registration Number
NCT01172821
Locations
🇺🇸

205.419.01068 Boehringer Ingelheim Investigational Site, Novi, Michigan, United States

🇺🇸

205.419.01071 Boehringer Ingelheim Investigational Site, Raleigh, North Carolina, United States

🇺🇸

205.419.01056 Boehringer Ingelheim Investigational Site, Union, South Carolina, United States

and more 122 locations

Safety and Effect of Mirapex(Pramipexole) Tablet Among Korean RLS

Completed
Conditions
Restless Legs Syndrome
First Posted Date
2010-07-27
Last Posted Date
2014-04-11
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
651
Registration Number
NCT01170091
Locations
🇰🇷

Boehringer Ingelheim Investigational Site 1, Busan, Korea, Republic of

🇰🇷

Boehringer Ingelheim Investigational Site 2, Busan, Korea, Republic of

🇰🇷

Boehringer Ingelheim Investigational Site 35, Daejeon, Korea, Republic of

and more 33 locations

Bioequivalence of a Fixed Dose Combination Tablet Containing 200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl Compared to RhinAdvil(R)(200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl) as a Fixed Dose Combination Tablet Administered in Healthy Volunteers.

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Pseudoephedrine-HCl
First Posted Date
2010-07-27
Last Posted Date
2018-08-31
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
47
Registration Number
NCT01170637
Locations
🇩🇪

1024.7.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy